Literature DB >> 33512386

Safety of CAR T-cell therapy in kidney transplant recipients.

Omar Mamlouk1, Ranjit Nair2, Swaminathan P Iyer2, Angelina Edwards3, Sattva S Neelapu2, Raphael E Steiner2, Sherry A Adkins2, Misha Hawkins2, Neeraj Saini4, Kartik Devashish2, Paolo Strati2, Sreedhar Mandayam1, Sairah Ahmed2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33512386      PMCID： PMC8109014          DOI： 10.1182/blood.2020008759

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

Review 1.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Authors:  Bertrand Coiffier; Clémentine Sarkozy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Cell-Free DNA and Active Rejection in Kidney Allografts.

Authors:  Roy D Bloom; Jonathan S Bromberg; Emilio D Poggio; Suphamai Bunnapradist; Anthony J Langone; Puneet Sood; Arthur J Matas; Shikha Mehta; Roslyn B Mannon; Asif Sharfuddin; Bernard Fischbach; Mohanram Narayanan; Stanley C Jordan; David Cohen; Matthew R Weir; David Hiller; Preethi Prasad; Robert N Woodward; Marica Grskovic; John J Sninsky; James P Yee; Daniel C Brennan
Journal:  J Am Soc Nephrol       Date:  2017-03-09       Impact factor: 10.121

Review 3.  Post-Transplantation Lymphoproliferative Disorders in Adults.

Authors:  Daan Dierickx; Thomas M Habermann
Journal:  N Engl J Med       Date:  2018-02-08       Impact factor: 91.245

4.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

5.  CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.

Authors:  Nolwenn Rabot; Matthias Büchler; Yohann Foucher; Anne Moreau; Celine Debiais; Marie-Christine Machet; Michelle Kessler; Emmanuel Morelon; Antoine Thierry; Christophe Legendre; Joseph Rivalan; Nassim Kamar; Jacques Dantal
Journal:  Transpl Int       Date:  2014-08-20       Impact factor: 3.782

6.  Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.

Authors:  Olli Dufva; Jan Koski; Pilvi Maliniemi; Aleksandr Ianevski; Jay Klievink; Judith Leitner; Petri Pölönen; Helena Hohtari; Khalid Saeed; Tiina Hannunen; Pekka Ellonen; Peter Steinberger; Matti Kankainen; Tero Aittokallio; Mikko A I Keränen; Matti Korhonen; Satu Mustjoki
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

Review 7.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors:  Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-25       Impact factor: 5.742

8.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Authors:  Loretta J Nastoupil; Michael D Jain; Lei Feng; Jay Y Spiegel; Armin Ghobadi; Yi Lin; Saurabh Dahiya; Matthew Lunning; Lazaros Lekakis; Patrick Reagan; Olalekan Oluwole; Joseph McGuirk; Abhinav Deol; Alison R Sehgal; Andre Goy; Brian T Hill; Khoan Vu; Charalambos Andreadis; Javier Munoz; Jason Westin; Julio C Chavez; Amanda Cashen; N Nora Bennani; Aaron P Rapoport; Julie M Vose; David B Miklos; Sattva S Neelapu; Frederick L Locke
Journal:  J Clin Oncol       Date:  2020-05-13       Impact factor: 50.717

9.  Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.

Authors:  Carlos A Ramos; Natalie S Grover; Anne W Beaven; Premal D Lulla; Meng-Fen Wu; Anastasia Ivanova; Tao Wang; Thomas C Shea; Cliona M Rooney; Christopher Dittus; Steven I Park; Adrian P Gee; Paul W Eldridge; Kathryn L McKay; Birju Mehta; Catherine J Cheng; Faith B Buchanan; Bambi J Grilley; Kaitlin Morrison; Malcolm K Brenner; Jonathan S Serody; Gianpietro Dotti; Helen E Heslop; Barbara Savoldo
Journal:  J Clin Oncol       Date:  2020-07-23       Impact factor: 50.717

10.  Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.

Authors:  Paolo Strati; Ankur Varma; Sherry Adkins; Loretta J Nastoupil; Jason Westin; Fredrick B Hagemeister; Nathan H Fowler; Hun J Lee; Luis E Fayad; Felipe Samaniego; Sairah Ahmed; Yiming Chen; Sandra Horowitz; Sara Arafat; Swapna Johncy; Partow Kebriaei; Victor Eduardo Mulanovich; Ella Ariza Heredia; Sattva S Neelapu
Journal:  Haematologica       Date:  2021-10-01       Impact factor: 9.941
View more
  7 in total

1.  Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation.

Authors:  Enver Akalin; Matthew R Weir; Suphamai Bunnapradist; Daniel C Brennan; Rowena Delos Santos; Anthony Langone; Arjang Djamali; Hua Xu; Xia Jin; Sham Dholakia; Robert N Woodward; Jonathan S Bromberg
Journal:  Kidney360       Date:  2021-09-28

Review 2.  Transplant Onconephrology in Patients With Kidney Transplants.

Authors:  Naoka Murakami; Allison B Webber; Vinay Nair
Journal:  Adv Chronic Kidney Dis       Date:  2022-03       Impact factor: 4.305

Review 3.  Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Authors:  Kevin Tang; Loretta J Nastoupil
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

Review 4.  Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.

Authors:  Brittany Schreiber; Maen Abdelrahim; Ala Abudayyeh; Naoka Murakami
Journal:  Semin Nephrol       Date:  2022-01       Impact factor: 4.472

Review 5.  Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?

Authors:  Umberto Maggiore; Alessandra Palmisano; Sebastiano Buti; Giulia Claire Giudice; Dario Cattaneo; Nicola Giuliani; Enrico Fiaccadori; Ilaria Gandolfini; Paolo Cravedi
Journal:  Transpl Int       Date:  2021-10-28       Impact factor: 3.842

6.  CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS.

Authors:  Wiebke Rösler; Andrea Bink; Marina Bissig; Lukas Imbach; Ewerton Marques Maggio; Markus G Manz; Thomas Müller; Patrick Roth; Elisabeth Rushing; Corinne Widmer; Thorsten Zenz; Seraina von Moos; Antonia M S Müller
Journal:  Hemasphere       Date:  2022-06-17

7.  A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia.

Authors:  Haibo Zhu; Qing Li; Yunyang Liu; Xuequan Feng; Qi Deng
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.